Roche drug may set new benchmark in MS, data suggest
October 08, 2015 at 11:30 AM EDT
Oct 8 (Reuters) - Roche's big new drug hope ocrelizumab cut multiple sclerosis relapses by nearly 50 percent compared with the older product Rebif in two large clinical trials, underscoring its potential in the main relapsing form of the disease.
